Table 3 Outcome measurements and adjusted intergroup differences
| Â | Unadjusted change | Odds ratio (95% CI) | |||
|---|---|---|---|---|---|
Outcome | Lidocaine | PRP | Treatment-time measurement interaction (p value) | Unadjusted | Adjusteda |
% meeting DASH-E improvement, no./total no. (%) | Â | Â | .307 | Â | Â |
 6–7 weeks | 11/24 (45.83) | 10/28 (35.71) |  | 1.37 (0.31 to 6.04) | 1.33 (0.31 to 5.71) |
 3 months | 20/24 (83.33) | 17/29 (58.62) |  | 4.73 (0.86 to 26.08) | 5.67 (0.98 to 32.74) |
 6 months | 18/25 (72.00) | 19/26 (73.08) |  | 0.90 (0.17 to 4.60) | 1.15 (0.22 to 5.95) |
 12 months | 17/24 (70.83) | 19/25 (76.00) |  | 0.71 (0.13 to 3.84) | 0.91 (0.17 to 4.88) |
% meeting VAS-P improvement, no./total no. (%) | Â | Â | .105 | Â | Â |
 6–7 weeks | 19/30 (63.33) | 13/31 (41.94) |  | 2.42 (0.67 to 8.76) | 2.67 (0.74 to 9.68) |
 3 months | 22/29 (75.86) | 16/28 (57.14) |  | 2.78 (0.68 to 11.38) | 2.92 (0.71 to 12.04) |
 6 months | 21/29 (72.41) | 22/26 (84.62) |  | 0.48 (0.10 to 2.37) | 0.50 (0.10 to 2.48) |
 12 months | 19/25 (76.00) | 20/22 (90.91) |  | 0.35 80.06 to 2.51) | 0.42 (0.06 to 3.03) |
Median DASH-E scores (IQR) | Â | Â | .429 | Â | Â |
 6-7 weeks | 30.17 (30.0) | 40.59 (34.86) |  | NA | NA |
 3 months | 16.49 (29.04) | 31.73 (34.94) |  | NA | NA |
 6 months | 12.93 (28.44) | 14.25 (26.66) |  | NA | NA |
 12 months | 7.50 (31.15) | 9.17 (24.17) |  | NA | NA |
Median VAS-P scores (IQR) | Â | Â | .441 | Â | Â |
 6–7 weeks | 4.00 (3.00) | 4.25 (4.75) |  | NA | NA |
 3 months | 2.00 (2.50) | 4.00 (5.00) |  | NA | NA |
 6 months | 2.00 (4.40) | 2.00 (3.50) |  | NA | NA |
 12 months | 2.00 (3.50) | 2.00 (4.00) |  | NA | NA |